III期非小细胞肺癌患者自适应放疗的剂量学获益
该研究基于13例III期非小细胞肺癌患者的每日锥形束CT合成图像,回顾性比较了图像引导放疗、等效应和等毒性三种策略的剂量学指标。结果显示自适应放疗可在保持靶区覆盖的同时降低同侧肺V20Gy和心脏V5%剂量,或在不超过同侧肺V20Gy的前提下对大体肿瘤体积进行中位10.0 Gy的剂量提升。
要点
- 图像引导放疗场景下PTV的D95%中位下降1.6 Gy,同侧肺V20Gy中位增加1.1%。
- 等效应场景保持PTV覆盖并将同侧肺V20Gy中位降低3.1%,心脏V5%中位降低2.9%。
- 等毒性场景下大体肿瘤体积中位剂量提升10.0 Gy,未增加同侧肺V20Gy和心脏V5%。
核心结论
- 即使不缩小安全边界,自适应放疗也能降低肺剂量并达到足够的靶区覆盖,或在不增加同侧肺受量的前提下提升靶区剂量。
- 两种策略在毒性和局部控制方面的临床获益应在前瞻性临床试验中评估。
研究设计与样本
- 回顾性研究,纳入13例III期非小细胞肺癌患者,将每日锥形束CT(共28、29、30次分次)转换为合成CT。
- 在首分次合成CT上制定治疗计划并原样转移至其余分次合成CT作为图像引导放疗场景,另在其余分次合成CT上生成等效应和等毒性两种计划。
主要发现
- 与原始计划预测剂量相比,图像引导放疗场景下PTV的D95%中位下降1.6 Gy ± 4.2 Gy,同侧肺V20Gy中位增加1.1% ± 4.4%。
- 等效应场景保持PTV覆盖,同侧肺V20Gy中位降低3.1% ± 3.6%,心脏V5%中位降低2.9% ± 6.4%。
- 等毒性处方下,大体肿瘤体积中位剂量提升10.0 Gy ± 8.1 Gy,未增加同侧肺V20Gy和心脏V5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Daily adaptive radiation therapy (ART) of patients with non-small cell lung cancer (NSCLC) lowers organs at risk exposure while maintaining the planning target volume (PTV) coverage. Thus, ART allows an isotoxic approach with increased doses to the PTV that could improve local tumor control. Herein we evaluate daily online ART strategies regarding their impact on relevant dose-volume metrics. METHODS: Daily cone-beam CTs (1 × n = 28, 1 × n = 29, 11 × n = 30) of 13 stage III NSCLC patients were converted into synthetic CTs (sCTs). Treatment plans (TPs) were created retrospectively on the first-fraction sCTs (sCT1) and subsequently transferred unaltered to the sCTs of the remaining fractions of each patient (sCT2-n) (IGRT scenario). Two additional TPs were generated on sCT2-n: one minimizing the lung-dose while preserving the D95%(PTV) (isoeffective scenario), the other escalating the D95%(PTV) with a constant V20Gy(lungipsilateral) (isotoxic scenario). RESULTS: Compared to the original TPs predicted dose, the median D95%(PTV) in the IGRT scenario decreased by 1.6 Gy ± 4.2 Gy while the V20Gy(lungipsilateral) increased in median by 1.1% ± 4.4%. The isoeffective scenario preserved the PTV coverage and reduced the median V20Gy(lungipsilateral) by 3.1% ± 3.6%. Furthermore, the median V5%(heart) decreased by 2.9% ± 6.4%. With an isotoxic prescription, a median dose-escalation to the gross target volume of 10.0 Gy ± 8.1 Gy without increasing the V20Gy(lungipsilateral) and V5%(heart) was feasible. CONCLUSIONS: We demonstrated that even without reducing safety margins, ART can reduce lung-doses, while still reaching adequate target coverage or escalate target doses without increasing ipsilateral lung exposure. Clinical benefits by means of toxicity and local control of both strategies should be evaluated in prospective clinical trials.
引用
- Hoppen L, Sarria GR, Kwok CS, et al. Dosimetric benefits of adaptive radiation therapy for patients with stage III non-small cell lung cancer. Radiat Oncol. 2023. PMID: 36814271. doi:10.1186/s13014-023-02222-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。